Did you know?

ChinaBio® Group is a consulting and advisory firm helping life science companies and investors achieve success in China. ChinaBio works with U.S., European and APAC companies and investors seeking partnerships, acquisitions, novel technologies and funding in China.  

Learn more >>

Free Newsletter

Have the latest stories on China's life science industry delivered to your inbox daily or weekly - free!

See preview >>

  Email address:
   

Apollomics Completes $124 Million C Financing for Cancer Drug Development

publication date: Nov 6, 2020

Apollomics, a Foster City-Hangzhou oncology company, completed a $124.2 million Series C financing led by Ping An Capital. The company has six assets in more than ten clinical trials in the US and China, a combination of mono- and combination- therapies that use the immune system or target molecular pathways to treat cancer. In 2016, Apollomics was spun out of CrownBio's drug development company with the goal of bringing China-developed immunotherapies to the US. It also in-licenses products for development in China and conducts China trials for its own products. More details...,

Share this with colleagues:


This article is available for purchase - please click here for details.

Sorry this page is available to subscribers only.
If you're not a subscriber why not subscribe today?

If you are already a subscriber, please login.

If you believe you should have received this message in error, please contact us.


 

To gain access to the members only content click here to subscribe.

You will be given immediate access to premium content on the site.

ChinaBio® News

Greg Scott BIO-Europe Interview
Greg Scott Interviewed at BIO-Europe Spring

How to bring your China assets to China in 8 minutes

Greg Scott Mendelspod Interview
"Mr. Bio in China."
Mendelspod Interview

Multinational pharma held to a higher standard in China

Partner Event
November 2-3, 2023 | Shanghai
November 7-8, 2023 | Digital